AstraZeneca (AZN) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard New custom dashboard
Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
05B10B15B20B25B30B35B40BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
01B2B4B5B6B8B9B10BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
011223445Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-10-8-6-4-21357Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
0510152025303540Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
012253850627588100Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
01B2B3B4B5B6B7B8BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
01B2B3B4B6B7B8B9BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Balance Sheet

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Quick Ratio

Total AssetsTotal Liabilities
025B50B75B100B125B150B175B200BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
025B50B75B100B125B150B175B200BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
010B20B30B40B50B60B70B80BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Liabilities

Total Stockholders Equity
08B15B22B30B38B45B52B60BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Shareholders Equity

Debt To Equity
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Asset Composition

Cash And Cash EquivalentsShort Term Investments
01B2B3B4B6B7B8B9BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Debt Structure

Short Term DebtLong Term Debt
05B10B15B20B25B30B35B40BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Key Metrics

AstraZeneca (AZN) quarterly earnings & revenue

AstraZeneca (AZN) reported revenue of $15.29B for Q1 2026, up 12.5% year-over-year, with net income of $3.08B and diluted EPS of $1.97.

Over the last four reported quarters, AstraZeneca generated $60.44B in revenue and $10.39B in net income.

AstraZeneca's next earnings report is scheduled for July 27, 2026 before market open; analysts estimate EPS of $2.52.

AstraZeneca quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q1 2026$15.29B+12.5%$3.08B$1.97
Q4 2025$15.50B+4.1%$2.33B$1.48
Q3 2025$15.19B+12.0%$2.53B$1.62
Q2 2025$14.46B+11.7%$2.45B$1.57
Q1 2025$13.59B+7.2%$2.92B$1.87
Q4 2024$14.89B+23.8%$1.50B$0.96
Q3 2024$13.56B+18.0%$1.43B$0.92
Q2 2024$12.94B+13.3%$1.93B$1.24

📈 Analysts estimate AZN EPS of $2.52 for the upcoming quarter. See AstraZeneca revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

AstraZeneca (AZN) — frequently asked questions

When does AstraZeneca (AZN) report earnings next?

AstraZeneca is expected to report earnings on July 27, 2026 before market open. Analysts estimate EPS of $2.52.

What was AZN's revenue last quarter?

AstraZeneca reported revenue of $15.29B in Q1 2026, up 12.5% from the same quarter a year earlier.

What was AZN's EPS last quarter?

AstraZeneca reported diluted EPS of $1.97 in Q1 2026.

Is AstraZeneca profitable?

AstraZeneca is currently profitable, with $10.39B in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)